Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma

Mark W. Clemens, L. Jeffrey Medeiros, Charles E. Butler, Kelly K. Hunt, Michelle A. Fanale, Steven Horwitz, Dennis D. Weisenburger, Jun Liu, Elizabeth A. Morgan, Rashmi Kanagal-Shamanna, Vinita Parkash, Jing Ning, Aliyah R. Sohani, Judith A. Ferry, Neha Mehta-Shah, Ahmed Dogan, Hui Liu, Nora Thormann, Arianna DiNapoli, Stephen LadeJorge Piccolini, Ruben Reyes, Travis Williams, Colleen M. McCarthy, Summer E. Hanson, Loretta J. Nastoupil, Rakesh Gaur, Yasuhiro Oki, Ken H. Young, Roberto N. Miranda

Research output: Contribution to journalArticle

160 Scopus citations

Abstract

Purpose. Breast implant-associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type of T-cell lymphoma that arises around breast implants. The optimal management of this disease has not been established. The goal of this study is to evaluate the efficacy of different therapies used in patients with BI-ALCL to determine an optimal treatment approach. Patients and Methods In this study, we applied strict criteria to pathologic findings, assessed therapies used, and conducted a clinical follow-up of 87 patients with BI-ALCL, including 50 previously reported in the literature and 37 unreported. A Prentice, Williams, and Peterson model was used to assess the rate of events for each therapeutic intervention. Results. Themedian and mean follow-up timeswere 45 and 30 months, respectively (range, 3 to 217 months). The median overall survival (OS) time after diagnosis of BI-ALCL was 13 years, and the OS rate was 93% and 89% at 3 and 5 years, respectively. Patients with lymphoma confined by the fibrous capsule surrounding the implant had better event-free survival (EFS) and OS than did patients with lymphoma that had spread beyond the capsule (P = .03). Patients who underwent a complete surgical excision that consisted of total capsulectomywith breast implant removal had better OS(P = .022) and EFS(P = .014) than did patients who received partial capsulectomy, systemic chemotherapy, or radiation therapy. Conclusion. Surgical management with complete surgical excision is essential to achieve optimal EFS in patients with BI-ALCL.

Original languageEnglish
Pages (from-to)160-168
Number of pages9
JournalJournal of Clinical Oncology
Volume34
Issue number2
DOIs
StatePublished - Jan 10 2016
Externally publishedYes

Fingerprint Dive into the research topics of 'Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Clemens, M. W., Medeiros, L. J., Butler, C. E., Hunt, K. K., Fanale, M. A., Horwitz, S., Weisenburger, D. D., Liu, J., Morgan, E. A., Kanagal-Shamanna, R., Parkash, V., Ning, J., Sohani, A. R., Ferry, J. A., Mehta-Shah, N., Dogan, A., Liu, H., Thormann, N., DiNapoli, A., ... Miranda, R. N. (2016). Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. Journal of Clinical Oncology, 34(2), 160-168. https://doi.org/10.1200/JCO.2015.63.3412